Fresenius Medical Care AG 6-K, filed Feb 9, 2024
Fresenius Medical Care AG (FMS)
About this 6-K
Fresenius Medical Care AG filed this 6-K on February 9, 2024.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2024
Commission file number: 001-32749
FRESENIUS MEDICAL CARE AG
(Translation of registrant's name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBITS
The following exhibits are being furnished with this Report:
| Exhibit 99.1 | Press Release issued on February 8, 2024. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: February 9, 2024
| Fresenius Medical Care AG | ||
| By: | /s/ Helen Giza | |
| Name: | Helen Giza | |
| Title: | Chief Executive Officer and Chair of the Management Board | |
| By: | /s/ Martin Fischer | |
| Name: | Martin Fischer | |
| Title: | Chief Financial Officer and member of the Management Board | |
Exhibit 99.1
| Press Release |
Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com
Emanuela Cariolagian T +1 213 706 0051 emanuela.cariolagian1@freseniusmedicalcare.com
Contact for analysts and investors Ilia Kürten T +49 6172 268 59 66 ilia.kuerten@freseniusmedicalcare.com
www.freseniusmedicalcare.com |
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies
| · | Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s 5008X Hemodialysis System. |
| · | This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S. |
| · | The 510(k) clearance allows the start of clinical evaluations and user-studies in the U.S., with a planned broad commercial launch of the 5008X Hemodialysis System in 2025. |
| · | The 5008X Hemodialysis System and companion FX CorAL dialyzer demonstrate the company’s global innovation leadership in medical device and membrane engineering technologies. |
Bad Homburg (February 8, 2024) Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s 5008X Hemodialysis System. Now the company wants to bring a new standard of care in dialysis therapy to people living with kidney diseases in the U.S.
| Page 1/3 |
“Making new and innovative therapies available to patients is core to our goal of improving the lives of people living with kidney diseases,” says Helen Giza, CEO for Fresenius Medical Care AG. “The 5008X Hemodialysis System demonstrates our company’s ability to innovate at scale. This innovation builds on the proven track record of our hemodialysis system series in Europe, Latin America and Asia Pacific. Helen Giza says: “We’re pleased to achieve this important milestone to bring a new standard of care in dialysis therapy to one of the world’s largest healthcare markets, where there is significant opportunity to make meaningful impact.”
Dialysis is a life-saving treatment for people whose kidneys are failing and who can no longer naturally filter their blood in order to remove excess water, solutes, and toxins from the body. Unlike conventional high-flux hemodialysis, which primarily employs diffusion to remove small molecules and fluid from the blood, high-volume hemodiafiltration incorporates both diffusion and convection techniques to eliminate larger molecules and effectively manage fluid replacement through convection.
The results of the recently published groundbreaking CONVINCE* study demonstrated that patients treated with high-volume hemodiafiltration experienced a remarkable 23% decrease in mortality rates compared to those treated with the more commonly used high-flux hemodialysis. This study was a multinational research study that compared these two types of hemodialysis techniques. It was a three-year trial performed at 61 dialysis centers in eight European countries.
Cleared for the start of U.S.-based clinical evaluations and user studies ahead of a planned broad market launch in 2025, the 5008X Hemodialysis System is one of Fresenius Medical Care’s latest medical device innovations, capable of providing industry-leading, high-volume hemodiafiltration dialysis therapy. Along with the companion FX CorAL dialyzer - already registered in the U.S. -, the 5008X Hemodialysis System combines the latest device engineering and cutting-edge membrane technologies required to make high-volume hemodiafiltration possible.
In the U.S. there is currently an estimated installed base of around 160.000 in-center hemodialysis machines across all service providers that could be replaced to adapt this new standard of care.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
*Funded by the European Union, conducted by the CONVINCE consortium, and led by the University Medical Center Utrecht, the international, randomized controlled CONVINCE trial marked a crucial milestone in comparing high-volume hemodiafiltration with standard, high-flux hemodialysis.
The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission’s opinions.
| Page 2/3 |
The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
| Page 3/3 |